Bio Usawa Receives the Ghana FDA Approval for BioUcenta (Biosimilar, Lucentis)

Shots: The Ghana FDA has approved BioUcenta, a biosimilar version of Lucentis (ranibizumab) for diabetic macular edema, age-related macular degeneration, and diabetic retinopathy The Ghana FDA approval followed a rigorous, science-based review referencing comprehensive data previously evaluated and accepted by the EMA BioUcenta is exclusively licensed to Bio Usawa for Sub-Saharan Africa by Bioeq AG Ref: Bio Usawa | Image: Bio Usawa | Press Release Related News: CuraTeQ Biologics Reports Positive P-III study…

ByDipanshu DixitJanuary 12, 2026

Bio Usawa Biotechnology and Bioeq AG Partner to Expand Access to Vision-Saving Treatments Across Sub-Saharan Africa

Shots: Bio Usawa Biotechnology and Bioeq AG entered into an agreement to make ranibizumab biosimilar for serious retinal diseases, accessible to millions in Sub-Saharan Africa The partnership gives Bio Usawa exclusive rights to register and market Bioeq’s ranibizumab biosimilar, BioUcenta, advancing access to essential biologics in Sub-Saharan Africa BioUcenta, an intravitreal injection, blocks abnormal retinal…

ByDipanshu DixitJuly 1, 2025

Insights+ Key Biosimilars Events of June 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of June, Organon entered into an agreement with Henlius…

BySenior EditorJuly 7, 2022

Bio Usawa Receives the Ghana FDA Approval for BioUcenta (Biosimilar, Lucentis)

Bio Usawa Biotechnology and Bioeq AG Partner to Expand Access to Vision-Saving Treatments Across Sub-Saharan Africa

Insights+ Key Biosimilars Events of June 2022

Contact US

FOLLOW US